Pharmaceuticals, Biotechnology and Life Sciences
The COVID-19 crisis continues to evolve rapidly and in recent days several governments in the markets in which Unibail-Rodamco-Westfield (“URW”)…
The World Health Organisation has issued a guideline to keep safety in schools. We have outlined the most important keys…
American president Donald Trump has announced radical measures last week; closing entering the USA for European citizens, curbing flights in general, and has announced a national emergency. Only two weeks earlier he was skeptical about the outbreak of the coronavirus in the USA.
How do pharmaceutical companies prophet from COVID-19? Do they make the profit?
IBM Watson Health and EBSCO Information Services Thursday announced a strategic collaboration aimed towards enhancing clinical decision support (CDS) and operations for healthcare providers and health systems.
@augustfalleraugustfaller goes on tour with a seminar
Amunix Pharmaceuticals, a tumor cancer-focused biopharmaceutical company has completed $73 million Series A financing round.
GenomSys has moved two of its teams to the BioPôle in Lausanne, to support the company’s growth and improve its accessibility to the Life Sciences community.
Abivax has doest the first patient with an iNKT agonist, ABX196, in a Phase 1/2 study to evaluate safety, tolerability and preliminary efficacy of the combination therapy. ABX196 is Abivax’s second compound in clinical development, following its lead candidate ABX464 in inflammatory diseases.
Mereo BioPharma has entered into a Securities Purchase Agreement with a new U.S.-based institutional healthcare investor. Under the terms of the Agreement, the institutional investor has agreed to make an investment of $3 million to purchase 12,252,715 of the Company’s ordinary shares (equivalent to 2,450,543 American Depository shares (ADSs)) at a price equivalent to 18.8 pence per share, which represents a 20% discount over Mereo’s closing share price of 23.5 pence on AIM on February 18, 2020.